Audentes Therapeutics

Audentes Therapeutics doing business as Astellas Gene Therapies, Inc. is a biotechnology company that serves as the Gene Therapy Center of Excellence. The company is divided into three divisions that specialize in gene therapy research, including technical operations, medical and development, and future commercialization of gene therapy programs.

Audentes Therapeutics was acquired by Astellas Pharma on January 15, 2020.

Audentes Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Genetics, Health Diagnostics sector. The company focuses on Biotechnology and has secured $83.4B in funding across 112 round(s). With a team of 251-500 employees, Audentes Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Audentes Therapeutics, raised $30.0M. Discover more about their projects, partnerships, and impact on our platform.